Sulgin Avexima, tablets 500 mg 10 pcs

Pharmacodynamics

Antimicrobial bacteriostatic agent. Mechanism of action is due to antagonism with paraaminobenzoic acid (PABA) and competitive inhibition of dihydropteroatsinthetase, which leads to disruption of tetrahydrofolic acid synthesis, necessary for purine and pyrimidine synthesis.

It inhibits the growth of E. coli and reduces the synthesis of thiamine, riboflavin, nicotinic acid in the intestine. SULGIN has bacteriostatic effect on Streptococcus spp., Staphylococcus spp., Escherichia coli, Shigella dysenteriae, Proteus vulgaris.

Pharmacokinetics

After oral administration, the drug is slightly absorbed from the digestive tract, resulting in high bacteriostatic concentration in the intestine.

Indications

– bacterial dysentery;

– colitis and enterocolitis;

– preparation for colon surgery.

Pharmacological effect

Pharmacodynamics

Antimicrobial bacteriostatic agent. The mechanism of action is due to antagonism with para-aminobenzoic acid (PABA) and competitive inhibition of dihydropteroate synthetase, which leads to disruption of the synthesis of tetrahydrofolic acid, necessary for the synthesis of purines and pyrimidines.

Inhibits the growth of Escherichia coli and reduces the synthesis of thiamine, riboflavin, and nicotinic acid in the intestines. SULGIN has a bacteriostatic effect on Streptococcus spp., Staphylococcus spp., Escherichia coli, Shigella dysenteriae, Proteus vulgaris.

Pharmacokinetics

After oral administration, the drug is slightly absorbed from the digestive tract, resulting in a high bacteriostatic concentration in the intestine.

Special instructions

In order to prevent crystalluria during treatment, patients should receive plenty of fluids (2-3 l/day).

Active ingredient

Sulfaguanidine

Composition

Active ingredient:
Sulfaguanidine monohydrate (Sulgin) – 500 mg.

Excipients:
potato starch – 90 mg, calcium stearate – 4 mg, sodium carboxymethyl starch – 6 mg.

Antimicrobial bacteriostatic agent. The mechanism of action is due to antagonism with para-aminobenzoic acid (PABA) and competitive inhibition of dihydropteroate synthetase, which leads to disruption of the synthesis of tetrahydrofolic acid, necessary for the synthesis of purines and pyrimidines. Inhibits the growth of Escherichia coli and reduces the synthesis of thiamine, riboflavin, and nicotinic acid in the intestines. Sulgin has a bacteriostatic effect on Streptococcus spp., Staphylococcus spp., Escherichia coli, Shigella dysenteriae, Proteus vulgaris.

Contraindications

Hypersensitivity to the components of the drug or other sulfonamides;
deficiency of glucose-6-phosphate dehydrogenase;
nephrourolithiasis;
porphyria;
B12 deficiency anemia;
pregnancy and lactation;
children under 3 years of age;
hyperbilirubinemia (in children).

Side Effects

From the digestive system: nausea, vomiting.

From the urinary system: crystalluria.

Allergic reactions: urticaria, exfoliative dermatitis.

Other: hypovitaminosis B, leukopenia, neuritis.

Interaction

Reduces the reliability of oral contraception.

Benzocaine and procaine reduce antimicrobial activity (PABA is released upon hydrolysis).

Non-steroidal anti-inflammatory drugs, hypoglycemic drugs (sulfonylurea derivatives), phenytoin and indirect anticoagulants increase the severity of the side effects of the drug.

Ascorbic acid and hexamethylenetetramine increase the risk of developing crystalluria.

Myelotoxic drugs increase the manifestations of hematotoxicity of the drug.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

4 years

Manufacturer

Irbitsky Chemical Plant, Russia